v3.26.3
Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
Common Stock [Member]
Preferred Stock [Member]
Series B1 Preferred Stock [Member]
Preferred Stock [Member]
Series B2 Preferred Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2024     $ 35,287,253 $ (34,578,101) $ 709,152
Balance, shares at Dec. 31, 2024 16,310          
Common stock issued for restricted stock units    
Common stock issued for restricted stock units, shares 3,361          
Issuance of common stock and pre-funded warrants, net of issuance costs of $275,000     5,038,574 5,038,574
Issuance of common stock and pre-funded warrants, net of issuance fees, shares 5,364          
Stock-based compensation     537,046 537,046
Net loss     (3,053,007) (3,053,007)
Partial conversion of convertible note at fair value     53,500 53,500
Partial conversion of convertible note at fair value, shares 500          
Balance at Mar. 31, 2025     40,916,373 (37,631,108) 3,285,265
Balance, shares at Mar. 31, 2025 25,535          
Balance at Dec. 31, 2024     35,287,253 (34,578,101) 709,152
Balance, shares at Dec. 31, 2024 16,310          
Common stock issued for restricted stock units, shares 3,402          
Issuance of common stock and pre-funded warrants, net of issuance fees, shares 5,364          
Net loss           (6,759,472)
Common stock issued for reverse stock split fractional share round up, shares 4          
Partial conversion of convertible note at fair value, shares 1,200          
Balance at Jun. 30, 2025     44,943,092 (41,337,573) 3,605,519
Balance, shares at Jun. 30, 2025 107,080          
Balance at Dec. 31, 2024     35,287,253 (34,578,101) 709,152
Balance, shares at Dec. 31, 2024 16,310          
Balance at Dec. 31, 2025 $ 2 48,554,214 (46,299,770) 2,254,446
Balance, shares at Dec. 31, 2025 202,362      
Balance at Mar. 31, 2025     40,916,373 (37,631,108) 3,285,265
Balance, shares at Mar. 31, 2025 25,535          
Common stock issued for restricted stock units    
Common stock issued for restricted stock units, shares 41          
Issuance of common stock and pre-funded warrants, net of issuance costs of $275,000     3,891,964 3,891,964
Issuance of common stock and pre-funded warrants, net of issuance fees, shares 2,193          
Exercise of pre-funded warrants     19,652 19,652
Exercise of pre-funded warrants, shares 78,607          
Stock-based compensation    
Net loss     (3,706,465) (3,706,465)
Common stock issued for reverse stock split fractional share round up    
Common stock issued for reverse stock split fractional share round up, shares 4          
Partial conversion of convertible note at fair value     68,250 68,250
Partial conversion of convertible note at fair value, shares 700          
Reversal of issuance costs in relation to November 2025 offering costs     46,853 46,853
Common stock issued for Molecule.ai Asset Acquisition    
Balance at Jun. 30, 2025     44,943,092 (41,337,573) 3,605,519
Balance, shares at Jun. 30, 2025 107,080          
Balance at Dec. 31, 2025 $ 2 48,554,214 (46,299,770) 2,254,446
Balance, shares at Dec. 31, 2025 202,362      
Common stock issued for restricted stock units
Common stock issued for restricted stock units, shares 4,478          
Issuance of common stock and pre-funded warrants, net of issuance costs of $275,000 $ 2 3,209,248 3,209,250
Issuance of common stock and pre-funded warrants, net of issuance fees, shares 223,880          
Exercise of pre-funded warrants $ 1   127 128
Exercise of pre-funded warrants, shares 128,411          
Stock-based compensation 35,018 35,018
Net loss   (2,152,471) (2,152,471)
Balance at Mar. 31, 2026 $ 5 51,798,607 (48,452,241) 3,346,371
Balance, shares at Mar. 31, 2026 559,131      
Balance at Dec. 31, 2025 $ 2 48,554,214 (46,299,770) 2,254,446
Balance, shares at Dec. 31, 2025 202,362      
Common stock issued for restricted stock units, shares 4,480          
Issuance of common stock and pre-funded warrants, net of issuance fees, shares 223,880          
Exercise of pre-funded warrants, shares 570,411          
Net loss           (5,298,010)
Common stock issued for reverse stock split fractional share round up, shares 32          
Balance at Jun. 30, 2026 $ 9 70,779,950 (51,597,780) 19,182,179
Balance, shares at Jun. 30, 2026 1,001,165 9,423 1,910      
Balance at Mar. 31, 2026 $ 5 51,798,607 (48,452,241) 3,346,371
Balance, shares at Mar. 31, 2026 559,131      
Common stock issued for restricted stock units
Common stock issued for restricted stock units, shares 2          
Exercise of pre-funded warrants $ 4 442 446
Exercise of pre-funded warrants, shares 442,000          
Stock-based compensation (7,511) (7,511)
Net loss (3,145,539) (3,145,539)
Issuance of Series B-1 preferred stock and Milestone Pre-Funded Warrants pursuant to Molecule.ai Second Amendment 300,176 300,176
Issuance of Series B-1 preferred stock pursuant to Molecule.ai Second Amendment, shares   270        
Prepaid share repurchase pursuant to Molecule.ai Second Amendment (266,012) (266,012)
Issuance of Series B-1 and Series B-2 Convertible Preferred Stock and 2026 Pre-Funded Warrants pursuant to the United Dogecoin Merger Agreement and PIPE, net of issuance costs of $1,207,032 18,710,161 18,710,161
Issuance of Series B-1 preferred stock pursuant to United Dogecoin Merger Agreement, shares   9,153 1,910      
Common stock issued for reverse stock split fractional share round up
Common stock issued for reverse stock split fractional share round up, shares 32          
Capitalized cost related to United Dogecoin replacement options 244,087 244,087
Balance at Jun. 30, 2026 $ 9 $ 70,779,950 $ (51,597,780) $ 19,182,179
Balance, shares at Jun. 30, 2026 1,001,165 9,423 1,910